Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9% - Here's Why

Key Points

• Shares fell about 5.9% intraday to $64.35 after Oruka priced an upsized $700M public offering at $72.50 per share, a large secondary that creates near‑term dilution and is the likely proximate cause of the sell‑off.
• Despite the drop, the company reported positive Phase 2a results for ORKA‑001 and published EVERLAST‑A interim data, prompting multiple firms (UBS, HC Wainwright, BTIG, Wedbush, Guggenheim) to raise price targets; the average analyst target is roughly $120.80 with a strong Buy consensus.
• Insiders have recently sold shares (23,765 in the last 90 days) though they still own about 24.7%, and Oruka remains a clinical‑stage, unprofitable biopharma with a market cap near $3.13 billion and negative EPS expectations.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s share price fell 5.9% during mid-day trading on Friday . The company traded as low as $64.08 and last traded at $64.3510. 835,942 shares were traded during mid-day trading, a decline of 11% from the average session volume of 939,022 shares. The stock had previously closed at $68.41.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and full‑year EPS forecasts for ORKA and maintained a Buy rating with a $120 target, signaling stronger expected financial trajectory and continued analyst confidence.
• Positive Sentiment: Company reported positive Phase 2a results for ORKA‑001 in moderate‑to‑severe plaque psoriasis — clinical progress that materially de‑risks the program if durability and safety are confirmed. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
• Positive Sentiment: Detailed interim results and slides from the EVERLAST‑A study (ORKA‑001) were posted and discussed in investor commentary, providing more data for analysts and institutions to model the program’s potential. ORKA Discusses Interim Results From EVERLAST‑A Study
• Positive Sentiment: Stifel Nicolaus reaffirmed its Buy view on ORKA, adding another institutional vote of confidence in the stock’s outlook. Stifel Keeps Buy Rating on Oruka Therapeutics
• Neutral Sentiment: Oruka was highlighted in a list of "small‑cap stocks that are on fire," which can boost retail attention but is not a substantive catalyst by itself. 5 Small‑Cap Stocks That Are On Fire Right Now
• Negative Sentiment: Oruka priced an upsized $700M public offering at $72.50 per share — a large secondary that creates near‑term dilution and typically pressures the stock; this is the most likely proximate cause of today’s sell‑off and elevated volume. Oruka Therapeutics Prices Upsized $700M Public Offering at $72.50

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ORKA. UBS Group boosted their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright boosted their price target on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday. BTIG Research boosted their price target on shares of Oruka Therapeutics from $78.00 to $151.00 and gave the company a "buy" rating in a research note on Monday. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research note on Monday. Finally, Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a "buy" rating in a research note on Monday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $120.80.

Oruka Therapeutics Stock Performance

The firm's 50 day moving average is $49.57 and its two-hundred day moving average is $36.87. The stock has a market capitalization of $3.13 billion, a PE ratio of -33.51 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. On average, analysts anticipate that Oruka Therapeutics, Inc. will post -2.25 EPS for the current year.

Insider Activity at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares of the company's stock, valued at $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00. Following the sale, the insider directly owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 23,765 shares of company stock worth $1,089,745. 24.69% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Legal & General Group Plc acquired a new position in Oruka Therapeutics during the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets grew its holdings in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after acquiring an additional 2,306 shares in the last quarter. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $39,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.